Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc.
2019 · Co-Development · $1.0B · Complete
Announcement Sentiment
94
Strongly positive
Outcome Score
77
Worked — the deal delivered on its rationale.
Regeneron and Alnylam entered a broad strategic collaboration to discover, develop, and commercialize RNAi therapeutics for eye and CNS diseases. Regeneron made a $400 million equity investment in Alnylam and the deal included development milestones and profit-sharing arrangements.